| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 09/16/1999 | WO1999046272A1 Serine peptidase modulators |
| 09/16/1999 | WO1999046258A1 SUBSTITUTED 2-(2,6-DIOXO-3-FLUOROPIPERIDIN-3-YL)-ISOINDOLINES AND THEIR USE TO REDUCE TNFα LEVELS |
| 09/16/1999 | WO1999046248A1 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors |
| 09/16/1999 | WO1999046242A1 Cycloalkene derivatives, process for producing the same, and use |
| 09/16/1999 | WO1999046237A1 Modulators of protein tyrosine phosphatases |
| 09/16/1999 | WO1999045918A1 Methods and compositions for delivery of taxanes |
| 09/16/1999 | WO1999045916A2 Novel methods for treating disorders in which docosahexaenoic acid (dha) levels are affected |
| 09/16/1999 | WO1999045910A2 Methods and compositions for treating and preventing mucositis |
| 09/16/1999 | WO1999045909A2 Use of nitrone compounds for the inhibition of angiogenesis |
| 09/16/1999 | WO1999045788A1 Food products having enhanced cocoa polyphenol content and processes for producing same |
| 09/16/1999 | WO1999035243A3 Extension of cellular lifespan, methods and reagents |
| 09/16/1999 | WO1999033355A3 Fat blend |
| 09/16/1999 | WO1999029878A3 Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system |
| 09/16/1999 | WO1999028304A9 Pdgf receptor kinase inhibitory compounds, their preparation and compositions |
| 09/16/1999 | CA2575850A1 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation |
| 09/16/1999 | CA2323490A1 inhibition of angiogenesis |
| 09/16/1999 | CA2322848A1 Novel methods for treating disorders in which docosahexaenoic acid (dha) levels are effected |
| 09/16/1999 | CA2322728A1 31 human secreted proteins |
| 09/16/1999 | CA2321026A1 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 09/16/1999 | CA2288240A1 Methods and compositions for delivery of taxanes |
| 09/15/1999 | EP0941991A1 2,4-Bis (4-amidino)phenyl furans as anti-pneumocystis carinii agents |
| 09/15/1999 | EP0941330A1 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (mpif-1), monocyte colony inhibitory factor (m-cif), and macrophage inhibitory factor-4 (mip-4) |
| 09/15/1999 | EP0941249A1 Novel histamine h2 receptor |
| 09/15/1999 | EP0941247A2 Peptide compounds useful for modulating fgf receptor activity |
| 09/15/1999 | EP0941242A2 Secreted proteins and polynucleotides encoding them |
| 09/15/1999 | EP0941224A1 Multivalent salts of pyridostigmine and related compounds |
| 09/15/1999 | EP0941122A2 Compositions and methods for polynucleotide delivery |
| 09/15/1999 | EP0941110A1 Uses of keratinocyte growth factor-2 |
| 09/15/1999 | EP0941089A2 Compositions and methods for treating or preventing inflammatory diseases |
| 09/15/1999 | EP0799188B1 Amides of mono and dicarboxylic acids with glycosamines, selectively active on the cannabinoid peripheral receptor |
| 09/15/1999 | EP0759899B1 Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities |
| 09/15/1999 | EP0741697B1 Amino acid derivatives and their use as phospholipase a2 inhibitors |
| 09/15/1999 | EP0733051B1 Bicyclic heterocycles as neurokinin a antagonists |
| 09/15/1999 | CN1228783A Thrombin inhibitor |
| 09/15/1999 | CN1228780A Phosphinic acid amides as matrix metalloprotease inhibitors |
| 09/15/1999 | CN1228779A Spirocyclic metalloprotease inhibitors |
| 09/15/1999 | CN1228773A Heterocyclic metalloprotease inhibitors |
| 09/15/1999 | CN1228771A 1,3-diheterocyclic metalloprotease inhibitors |
| 09/15/1999 | CN1228767A Bidentate metalloprotease inhibitors |
| 09/15/1999 | CN1228697A Method for in vivo reduction of iron levels and compositions useful therefor |
| 09/15/1999 | CN1045088C Purine and guanine compounds as inhibitors of PNP |
| 09/14/1999 | US5952510 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives having PDE IV and cytokine inhibiting activity |
| 09/14/1999 | US5952499 Therapeutic compound-fatty acid conjugates |
| 09/14/1999 | US5952483 Human IκB-β |
| 09/14/1999 | US5952382 Inhibiting the biological effects of an overregulation of retinoid acid receptors and/or of a hypervitaminosis a; treating skin disorder, eye vision defects, skin aging |
| 09/14/1999 | US5952373 Applying to the skin an effective amount of one or more flavonoids |
| 09/14/1999 | US5952369 Pyrrolidinyl hydroxamic acid compounds and their production process |
| 09/14/1999 | US5952368 5-aroylpyrrol-2-ylmethylarene derivatives |
| 09/14/1999 | US5952321 Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| 09/14/1999 | US5952295 Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract |
| 09/14/1999 | US5952001 Preparing pharmaceutical, dermatological or cosmetic preparations for the prevention or treatment of allergic manifestations such as skin allergy, bronchial asthma, or inflammation, or as free radical scavengers |
| 09/14/1999 | US5951982 Administering an antibody thaat binds an epitope of vcd44; antitumor,-metastasis and carciogenic agents |
| 09/14/1999 | US5951971 Eye-drops for treatment of eye disorders and surrounding area comprising cyclosporin and surfactant selected from polyoxyethylene fatty acid esters, polyoxyethylene alkylphenol ether and polyoxyethylene alkyl ethers |
| 09/14/1999 | CA2150483C Pyrazoles and pyrazolopyrimidines |
| 09/10/1999 | WO1999045127A2 Enhanced prodrug activation |
| 09/10/1999 | WO1999045126A2 Enhanced prodrug activation |
| 09/10/1999 | WO1999045031A2 Cd147 binding molecules as therapeutics |
| 09/10/1999 | WO1999045024A1 Cholenic acid amides and pharmaceutical compositions thereof |
| 09/10/1999 | WO1999045009A1 Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| 09/10/1999 | WO1999044995A1 Novel pyridazine derivatives and drugs containing the same as the active ingredient |
| 09/10/1999 | WO1999044994A1 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists |
| 09/10/1999 | WO1999044989A1 Matrix metalloproteinase inhibitors |
| 09/10/1999 | WO1999044623A1 Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid |
| 09/10/1999 | WO1999044602A1 Inflammatory cell inhibitors |
| 09/10/1999 | WO1999044591A1 Extended release dosage form |
| 09/10/1999 | WO1999044584A1 Emulsion preconcentrates containing cyclosporin or a macrolide |
| 09/10/1999 | WO1999021617B1 Allosteric adenosine receptor modulators |
| 09/10/1999 | CA2322749A1 Cd147 binding molecules as therapeutics |
| 09/10/1999 | CA2322664A1 Enhanced prodrug activation |
| 09/10/1999 | CA2322486A1 Inflammatory cell inhibitors |
| 09/10/1999 | CA2322207A1 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists |
| 09/10/1999 | CA2321737A1 Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid |
| 09/10/1999 | CA2317502A1 Matrix metalloproteinase inhibitors |
| 09/10/1999 | CA2249041A1 Novel compounds |
| 09/08/1999 | EP0940391A2 Quinoline derivatives as tachykinin NK3 receptor antagonists |
| 09/08/1999 | EP0939821A2 G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 09/08/1999 | EP0939815A1 IDENTIFICATION OF Bap-1, A PROTEIN THAT BINDS TO INTEGRIN AND IS INVOLVED IN INTEGRIN-MEDIATED SIGNAL TRANSDUCTION |
| 09/08/1999 | EP0939807A2 Secreted proteins and polynucleotides encoding them |
| 09/08/1999 | EP0939804A1 NEUTROKINE alpha |
| 09/08/1999 | EP0939654A1 Association of no syntase inhibitors with trappers of oxygen reactive forms |
| 09/08/1999 | EP0939642A1 Novel ectoparasite saliva proteins and apparatus to collect such proteins |
| 09/08/1999 | EP0939623A1 Oral delayed immediate release formulation and method of preparation therefor |
| 09/08/1999 | EP0799205B1 1,4,4-(trisubstituted)cyclohex-1-ene derivatives as pde iv- and tnf-inhibitors |
| 09/08/1999 | EP0790981B1 Aryloxycycloalkenyl and aryloxyiminocycloalkenylhydroxyureas as 5-lipoxygenase inhibitors |
| 09/08/1999 | EP0706393B1 Immunosuppressant and antiallergic compounds, e.g. n-(3-oxohexanoyl) homoserine lactone |
| 09/08/1999 | EP0656906B1 A novel endothelial cell molecule mediating lymphocyte binding in man |
| 09/08/1999 | CN1228091A Substituted 6,6-hetero-bicyclic derivatives |
| 09/08/1999 | CN1228090A Naphthyridines with affect IL-4 and G-CSF |
| 09/08/1999 | CN1228080A Novel immunotherapeutic agents and their use in production of cytokine levels |
| 09/08/1999 | CN1228024A Use of K-252A derivative for treatment of peripheral or central nerve disorders, and cytokine overproduction |
| 09/08/1999 | CN1227871A Nuclein structural body for gene treating method |
| 09/07/1999 | US5948898 Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
| 09/07/1999 | US5948804 Anaesthetic premedication |
| 09/07/1999 | US5948795 Benzothiopene compounds, and uses and formulations thereof |
| 09/07/1999 | US5948777 Cannabinoid receptor agonists |
| 09/07/1999 | US5948638 TNF receptor death domain ligand proteins |
| 09/07/1999 | US5948402 Method of using IL-11 for treating antibiotic induced diarrhea |
| 09/07/1999 | US5947708 Axial flow valve system for linear compressor |
| 09/07/1999 | CA2147881C Dithiocarbamates for the treatment of atherosclerosis and other cardiovascular and inflammatory diseases |
| 09/02/1999 | WO1999043840A1 Self-regulated apoptosis of inflammatory cells by gene therapy |